Status:
COMPLETED
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
Lead Sponsor:
University of Aarhus
Conditions:
Peritoneal Metastases
Peritoneal Carcinomatosis
Eligibility:
All Genders
18+ years
Brief Summary
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has prolonged the survival substantially for selected patients with peritoneal metastases from colorectal cancer.Bleeding a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Cytoreductive surgery with HIPEC patients:
- Able to give informed consent
- Age ≥ 18 years
- Diagnosed with peritoneal metastases from colorectal cancer
- Planned to undergo cytoreductive surgery with HIPEC
- Minimally invasive rectal cancer patients:
- Able to give informed consent
- Age ≥ 18 years
- Diagnosed with rectal cancer
- Planned to undergo minimal invasive rectal cancer resection with one of: total mesorectal excision, partial mesorectal excision or abdominoperineal excision
- Exclusion Criteria (both groups):
- Thromboembolic event within 90 days before surgery
- Secondary malignancy within previous 5 years or concomitant, except non-melanoma skin cancer.
Exclusion
Key Trial Info
Start Date :
April 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 27 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04744688
Start Date
April 6 2021
End Date
May 27 2024
Last Update
May 29 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Aarhus N, Denmark, 8200
2
Thrombosis and Haemostasis Research Unit, Department for Clinical Biochemistry, Aarhus University Hospital
Aarhus N, Denmark, 8000